VEGF and Breast Cancer Survival
Author Information
Author(s): Linderholm B, Tavelin B, Grankvist K, Henriksson R
Primary Institution: Umeå University Hospital
Hypothesis
Does vascular endothelial growth factor (VEGF) predict local relapse and survival in radiotherapy-treated node-negative breast cancer?
Conclusion
VEGF165 is a predictor of relapse-free and overall survival in node-negative breast cancer patients treated with radiotherapy.
Supporting Evidence
- Significant associations were found between VEGF and oestrogen receptor content.
- Higher VEGF content was associated with reduced relapse-free and overall survival.
- VEGF was suggested as the only predictor of overall survival in multivariate analysis.
Takeaway
This study found that a substance called VEGF can help predict how well breast cancer patients will do after treatment.
Methodology
VEGF content was measured in tumor cytosols using an enzymatic immunoassay, and associations with relapse-free and overall survival were analyzed.
Limitations
The study may not account for all factors influencing survival and relapse.
Participant Demographics
Median age of participants was 56 years.
Statistical Information
P-Value
0.0113 for RFS, 0.0075 for OS
Confidence Interval
95% CI = 0.97–13.37 for OS, 95% CI = 1.07–24.59 for T1 tumours, 95% CI = 1.26–86.38 for ER-positive tumours
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website